FDA Approves New Heart Pump From Abiomed

Abiomed has announced that it received FDA approval for its Impella RP System, the first percutaneous single access heart pump that provides support to the right side of the heart. The approval, under a Humanitarian Device Exemption (HDE), is based on results of the single arm Recover Right study, in which 30 patients were enrolled. The overall survival rate was 73% at 30 days. … Click here to read the full post on Forbes.    
Source: CardioBrief - Category: Cardiology Authors: Tags: Heart Failure Interventional Cardiology & Surgery Policy & Ethics Abiomed catheterization Impella Source Type: blogs